🇺🇸 SPM 927 in United States
5 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 5
Most-reported reactions
- Bradycardia — 1 report (20%)
- Convulsion — 1 report (20%)
- Hypotension — 1 report (20%)
- Sopor — 1 report (20%)
- Suicide Attempt — 1 report (20%)
Other Neurology approved in United States
Frequently asked questions
Is SPM 927 approved in United States?
SPM 927 does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for SPM 927 in United States?
UCB Pharma is the originator. The local marketing authorisation holder may differ — check the official source linked above.